165 related articles for article (PubMed ID: 33820647)
1. [Patients treated with palbociclib and endocrine therapy for metastatic breast cancer: Can we predict the occurrence of severe early hematological toxicity?].
Vazquez L; Arnaud A; Grenier J; Debourdeau P
Bull Cancer; 2021 May; 108(5):544-552. PubMed ID: 33820647
[TBL] [Abstract][Full Text] [Related]
2. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
Turner NC; Ro J; André F; Loi S; Verma S; Iwata H; Harbeck N; Loibl S; Huang Bartlett C; Zhang K; Giorgetti C; Randolph S; Koehler M; Cristofanilli M;
N Engl J Med; 2015 Jul; 373(3):209-19. PubMed ID: 26030518
[TBL] [Abstract][Full Text] [Related]
3. Real-world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia.
Sun J; Zhong X; Ma J; Sun W; Han HS; Soliman HH; Loftus LS; Costa RLB; Armaghani AJ; Soyano-Muller AE; Czerniecki BJ; Lee MC; Kiluk JV; Khakpour N; Hoover SJ; Laronga C; Khong HT
Cancer Med; 2021 Nov; 10(21):7665-7672. PubMed ID: 34590788
[TBL] [Abstract][Full Text] [Related]
4. Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer.
Ham A; Kim MH; Kim GM; Kim JH; Kim JY; Park HS; Park S; Cho YU; Park BW; Kim SI; Sohn J
Breast Cancer Res Treat; 2020 Aug; 183(1):107-116. PubMed ID: 32577940
[TBL] [Abstract][Full Text] [Related]
5. Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Varella L; Eziokwu AS; Jia X; Kruse M; Moore HCF; Budd GT; Abraham J; Montero AJ
Breast Cancer Res Treat; 2019 Jul; 176(2):429-434. PubMed ID: 30895534
[TBL] [Abstract][Full Text] [Related]
6. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
[TBL] [Abstract][Full Text] [Related]
7. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.
DeMichele A; Clark AS; Tan KS; Heitjan DF; Gramlich K; Gallagher M; Lal P; Feldman M; Zhang P; Colameco C; Lewis D; Langer M; Goodman N; Domchek S; Gogineni K; Rosen M; Fox K; O'Dwyer P
Clin Cancer Res; 2015 Mar; 21(5):995-1001. PubMed ID: 25501126
[TBL] [Abstract][Full Text] [Related]
8. The safety and efficacy of palbociclib in the treatment of metastatic breast cancer.
Ettl J; Harbeck N
Expert Rev Anticancer Ther; 2017 Aug; 17(8):661-668. PubMed ID: 28649895
[TBL] [Abstract][Full Text] [Related]
9. Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development.
Clark AS; Karasic TB; DeMichele A; Vaughn DJ; O'Hara M; Perini R; Zhang P; Lal P; Feldman M; Gallagher M; O'Dwyer PJ
JAMA Oncol; 2016 Feb; 2(2):253-60. PubMed ID: 26633733
[TBL] [Abstract][Full Text] [Related]
10. Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval.
Kish JK; Ward MA; Garofalo D; Ahmed HV; McRoy L; Laney J; Zanotti G; Braverman J; Yu H; Feinberg BA
Breast Cancer Res; 2018 May; 20(1):37. PubMed ID: 29720233
[TBL] [Abstract][Full Text] [Related]
11. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
[TBL] [Abstract][Full Text] [Related]
12. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).
Verma S; Bartlett CH; Schnell P; DeMichele AM; Loi S; Ro J; Colleoni M; Iwata H; Harbeck N; Cristofanilli M; Zhang K; Thiele A; Turner NC; Rugo HS
Oncologist; 2016 Oct; 21(10):1165-1175. PubMed ID: 27368881
[TBL] [Abstract][Full Text] [Related]
13. Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.
Tamura K
Jpn J Clin Oncol; 2019 Dec; 49(11):993-998. PubMed ID: 31665472
[TBL] [Abstract][Full Text] [Related]
14. Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study.
Waller J; Mitra D; Mycock K; Taylor-Stokes G; Milligan G; Zhan L; Iyer S
J Glob Oncol; 2019 May; 5():JGO1800239. PubMed ID: 31050919
[TBL] [Abstract][Full Text] [Related]
15. Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors.
Dawood S; Chiu JW; Huang CS; Nag S; Sookprasert A; Yap YS; Md Yusof M
Curr Med Res Opin; 2020 Aug; 36(8):1363-1373. PubMed ID: 32544344
[TBL] [Abstract][Full Text] [Related]
16. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients.
Tamura K; Mukai H; Naito Y; Yonemori K; Kodaira M; Tanabe Y; Yamamoto N; Osera S; Sasaki M; Mori Y; Hashigaki S; Nagasawa T; Umeyama Y; Yoshino T
Cancer Sci; 2016 Jun; 107(6):755-63. PubMed ID: 26991823
[TBL] [Abstract][Full Text] [Related]
18. Time to treatment failure of palbociclib and letrozole as second-line therapy or beyond in hormone receptor-positive advanced breast cancer.
Schickli MA; Berger MJ; Lustberg M; Palettas M; Vargo CA
J Oncol Pharm Pract; 2019 Sep; 25(6):1374-1380. PubMed ID: 30134767
[TBL] [Abstract][Full Text] [Related]
19. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
20. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D
Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
